TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03644667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Triple IS
Description: Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Triple IS
Description: Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol.
Study: NCT04357483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flowable thrombin containing collagen hemostat matrix
Description: A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thrombin coated L-dopa contained collagen patch
Description: A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
Study: NCT04632316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-Fludarabine (Cy/Flu)
Description: Lymphodepleting conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oNKord®
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Study: NCT02315534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
Study: NCT02590211

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive, emotional and clinical assessment
Description: Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive, emotional and clinical assessment
Description: Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
Study: NCT02315534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
Study: NCT00658463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02451462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT00603122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ascent protocol
Description: ascent protocol for the two groups has different acclimatization time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ascent protocol
Description: ascent protocol for the two groups has different acclimatization time
Study: NCT03256604

Intervention type: DIAGNOSTIC_TEST
Intervention: left-over sputum
Description: Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
Study: NCT01336153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC601
Description: group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
Study: NCT00825903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
Study: NCT04193592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
Study: NCT01907425

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study: NCT02590211

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive, emotional and clinical assessment
Description: Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
Study: NCT02048085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
Study: NCT00930228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
Study: NCT03209466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate at 0.125%
Description: Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator with physiological saline sterile solution
Description: Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
Study: NCT03543137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Prototype Mini lozenge
Description: A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Mini Lozenge
Description: A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study: NCT00465023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Once a day, 5 days a week (Monday-Friday) for 3 weeks.
Study: NCT02110095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosure Laser System
Description: Picosure Laser System for the Treatment of Unwanted Tattoos
Study: NCT01239823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise without vibration
Description: Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
Study: NCT00176462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminopterin
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunomycin
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study: NCT03795233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant G3 capsules
Description: After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin alone
Description: Standard of care will be provided with oral vancomycin therapy.
Study: NCT00906516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuradiab in combination with Bevacizumab (Avastin)
Description: Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient.
Study: NCT01205464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
Study: NCT01337921

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-strain Probiotic
Description: Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain Probiotic
Description: Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
Study: NCT00283153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Affect Recognition Training
Description: A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stories of Emotional Inference
Description: Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
Study: NCT03174028

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic pull-through
Description: laparoscopic pull-through

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laparoscopic pull-through
Description: laparoscopic pull-through
Study: NCT00176462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunomycin
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-thioguanine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT00176462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT02599233

Intervention type: OTHER
Intervention: Telephone conctact at 3 months
Description: Patients will be contacted at 3 months post-surgery for pain questionnaires.

Intervention type: OTHER
Intervention: In hospital pain evaluation
Description: Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.

Intervention type: OTHER
Intervention: In hospital questionnaires
Description: Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
Study: NCT01821703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3045697
Description: Administered as oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Administered as capsule
Study: NCT03230760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
Study: NCT01821703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsule
Study: NCT00556816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: on demand clinic
Description: Outpatient on demand clinic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: conventional outpatient clinic
Study: NCT01045694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid - Triamcinolone Acetonide
Description: Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Single injection of 1 - 3 mL of 2% Lidocaine
Study: NCT03156283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SleepWell24 Application
Description: An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy